

AMENDMENTS TO THE CLAIMS

The listing of claims provided below will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-18. (Cancelled)

19. (Currently Amended) A method for prevention of chronic refractory graft rejection in a human lung transplant recipient comprising administering to the recipient, prior to the development of symptoms associated with acute transplant rejection, (i) an aerosolized composition comprising a therapeutic dose of cyclosporine, to thereby prevent chronic refractory graft rejection in the human lung transplant recipient.

20. (Previously presented) The method of claim 19, wherein the cyclosporine is administered as a dry powder in combination with a propellant.

21. (Previously presented) The method of claim 19, wherein the cyclosporine is dissolved in an organic solvent.

22. (Previously presented) The method of claim 19, 20 or 21 wherein the dose of cyclosporine is sufficient to achieve deposition levels ranging between 15 and 30 mg in a lung.

23. (Cancelled)

24. (Previously Presented) The method of claim 19, 20 or 21 wherein the aerosolized composition is co-administered with an effective amount of one or more other agent selected from the group consisting of an immunosuppressive agent and an anti-inflammatory reagent.

25-29. (Cancelled)

30. (Currently Amended) A method for prevention of chronic refractory graft rejection in a non-lung transplant recipient comprising administering to the non-lung transplant recipient prior to the development of symptoms ~~associated with acute transplant rejection~~, an aerosolized composition comprising a dose of cyclosporine dissolved in an organic solvent, in an amount effective to prevent graft rejection, thereby preventing chronic refractory graft rejection in the non-lung transplant recipient.

31. (Currently Amended) A method for prevention of chronic refractory graft rejection in a non-lung transplant recipient comprising administering to the non-lung transplant recipient, prior to the development of symptoms ~~associated with acute transplant rejection~~, an aerosolized composition comprising :

(i) a dose of cyclosporine in dry powder form in an amount effective to prevent graft rejection; and

(ii) a propellant,

thereby preventing chronic refractory graft rejection in the non-lung transplant recipient.

32-48. (Cancelled)

49. (Previously Presented) The method of claim 19, wherein the first administration occurs within 31 days of transplantation.

50. (Previously Presented) The method of claim 49, wherein the first administration occurs within 10 days of transplantation.

51. **(Previously Presented)** The method of claim 30, wherein the first administration occurs within 31 days of transplantation.
52. **(Previously Presented)** The method of claim 51, wherein the first administration occurs within 10 days of transplantation.
53. **(Previously Presented)** The method of claim 31, wherein the first administration occurs within 31 days of transplantation.
54. **(Previously Presented)** The method of claim 53, wherein the first administration occurs within 10 days of transplantation.